[Suppression of bone marrow in neonatal herpes simplex virus infection under virustatic therapy with adenine arabinoside-5'-monophosphate (author's transl)].
The case of a generalized neonatal herpes-simplex-virus infection with lethal outcome is presented. Therapy with adenine arabinoside-5'-monophosphate (ARA AMP) was employed with a good virustatic effect. Suppression of bone marrow and a possible immunological suppression was seen at low dose level already. Therefore in newborn and prematures we suggest a cautious regimen in employing this substance, which was until now considered to have no serious side effects.
D001088:Arabinonucleotides / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy*; D001084:Vidarabine Phosphate / Q000009:adverse effects* / Q000627:therapeutic use
D001088:Arabinonucleotides; D001084:Vidarabine Phosphate
Knochenmarksdepression bei einer Neugeborenen-Herpes-Sepsis unter virustatischer Therapie mit Adeninarabinosid-5'-Monophosphat.